The relationship between charge and in-vivo bioactivity is (Blum and Gupta, 1985), and therefore, as might Gynaecology, John Radcliffe Hospital, Oxford OX3 9DU, UK be expected, have a greater in-vivo bioactivity (Mulders et al., 
glycoform species to suggest that the less acidic forms are the The immunopotency and in-vitro biopotency of clinical more bioactive in an animal model (Vitt et al., 1998) and for batches of Gonal-F ® and Puregon ® (recombinant human Puregon glycoforms on a molar basis, in human pre-ovulatory follicle stimulating hormones) were compared and their and granulosa-lutein cells (Harris et al., 1998) . Overall, whereas carbohydrate chains investigated for charge heterogeneity the less acidic species may have greater receptor binding, it and internal carbohydrate complexity. Immunopotency seems that a slow clearance rate is the principal determinant (IU/pmol) for both Gonal-F and Puregon was 0.35 ⍨ 0.01 of in-vivo bioactivity which is consequently greater for the and biopotency (ED 50 , pmol/l) was similar, being 7.3 ⍨ 0.6 more acidic forms (de Leeuw et al., 1996) . Furthermore, and 5.4 ⍨ 0.2 respectively. Charge distributions were deglycosylated variants of FSH act as hormone antagonists, essentially the same with no difference either in median and forms possessing immuno-but not bioactivity do occur isoelectric point (pI) (between 4.26 and 4.50), or in the naturally and may be important in gonadal function by causing bulk of material fractionated between pI 4 and 5 (66.0 ⍨ receptor blockade (Dahl et al., 1988) . The evidence regarding 1.8% Gonal-F and 72.0 ⍨ 1.8% Puregon). However, there the endocrine control and physiological importance of these were minor differences in charge at extremes of pI, Gonalglycoforms has recently been reviewed (Lambert et al., 1998) . F being slightly more acidic: 18.2% Gonal-F versus 9. 8% In brief, glycoform synthesis, secretion and the composition Puregon at pI 3.5-4.0 (P ⍧ 0.03) and 6.7% Gonal-F versus of the mixture in blood is related to FSH concentration 10.7% Puregon at pI 5.0-5.5 (P ⍧ 0.03). Carbohydrate (probably mediated via changes in gonadotrophin-releasing complexity was the same: 9.3 versus 10.9 (complex), 76.6 hormone pulsatility) and oestradiol concentrations (Wide and versus 78.6 (intermediate) and 14.1 versus 10.5% (simple). Naessén 1994; Chappel, 1995; Ulloa-Aguirre et al., 1995 ; In summary, Gonal-F and Puregon have similar immuno- Wide et al., 1996; Anobile et al., 1998) . The particular acidity potency, in-vitro biopotency and internal carbohydrate of the FSH glycoforms in blood varies considerably at different complexity, differing slightly in charge heterogeneity, stages of the menstrual cycle most markedly at mid-cycle Gonal-F having more acidic glycoforms. We conclude them when there is an increase in the less acidic, less complex to be intrinsically very similar, expecting no difference in species (Padmanabhan et al., 1988; Wide and Bakos, 1993 ; clinical efficacy on the basis of respective structure. Zambrano et al., 1995; Anobile et al., 1998) . Further, there is Key words: FSH/glycoforms/Gonal-F/Puregon/rFSH a wealth of data (see Lambert et al., 1998) on changes in the mixture of secreted glycoforms of FSH and LH in a variety of pathologies and such observations have led to speculation as to whether the different forms may have different biological Introduction activities. The increasing evidence surrounding the regulation of FSH FSH is a dimeric glycoprotein with an α protein subunit common to LH and thyroid stimulating hormone from the glycoforms and the possibility of their having different functions could have important implications for the use of FSH in pituitary gland and human chorionic gonadotrophin (HCG) from the placenta. The α subunit is bound non-covalently to assisted reproduction programmes in which rFSH is playing an increasingly important part. Such products have the advanta β subunit unique to each hormone which together confer biological specificity. There are two carbohydrate chains ages of ease of supply in unlimited quantity, and the stringent quality control procedures employed in their production result N-linked to asparagine residues on each FSH subunit (Baenziger and Green, 1988) and these comprise~28% of in minimal between-batch variability as compared with the significant batch-to-batch differences seen in some urinary the hormone mass. There is marked variability in both the oligosaccharide composition, branching pattern and overall preparations (Rodgers et al., 1995) .
Two rFSH preparations are in current clinical use, Gonal-F ® (Ares Serono, Geneva, Switzerland) and Puregon ® (NV Organon, Oss, The Netherlands). Both are produced from Chinese hamster ovary cells transfected with the human FSH subunit genes. Gonal-F is subsequently purified from the cell culture supernatant by an ultrafiltration followed by five chromatographic stages including reversed-phase highperformance liquid chromatography (HPLC) with an immunoaffinity procedure being the principal purification step (Howles, 1996) . The chromatographic stages in the purification of Puregon include anion and cation exchange, hydrophobic interaction and size exclusion (Olijve et al., 1996) . Both preparations have proven efficacy in clinical trials (Recombinant FSH Study Group, 1995; Out et al., 1995; Bergh et al., 1997) . We have previously characterized an early batch of Puregon with regard to in-vitro biopotency, charge distribution (Lambert et al., 1995) and internal carbohydrate complexity for oestradiol production (mean Ϯ SD, n ϭ 3 replicates) in the rat Sertoli bioassay system for Puregon (similar curve for Gonal-F not (Harris et al., 1996) and found clear differences between these shown for clarity). The responses shown are absolute oestradiol parameters in naturally occurring and urinary FSH preparations production; unstimulated oestradiol concentrations, being below the used in assisted reproduction programmes.
assay detection limit (125 pmol/l), did not permit data expression
The aims of this study were to extend our earlier findings as increase over basal.
by determining whether or not the clinical material in the current batches of Gonal-F and Puregon is different, comparing UK) and anti-17β-oestradiol (Advance Biotechnologies, Leatherhead, Surrey, UK). The cross-reactivities of this antiserum were: oestradiol, 100%; oestrone Ͻ2.0%; oestriol, 0.08%; progesterone Ͻ0.02%;
Materials and methods
androstenedione 0.056%; dehydroepiandrosterone 0.12%; testosterone The Sertoli cell bioassay for FSH Ͻ0.02%. Quality control samples (250, 750, 2500, 7500, 15 000 and 25 000 pmol/l) were assayed in duplicate in each assay. IntraSertoli cells were isolated from 8-10 day old rats following a previously published method (Van Damme et al., 1979) with some and inter-assay coefficients of variation were Ͻ10% and Ͻ17% respectively over the range 250-25 000 pmol/l. modifications. Briefly the testes were removed, decapsulated, cut into small pieces and dispersed by mechanical agitation (rotating paddle, Chromatofocusing of FSH preparations 400 r.p.m. at 37°C) in the presence of collagenase (0.03% w/v) in Dulbecco's modified Eagle's medium (DMEM) for 30 min. The cells All buffers were prepared in distilled deionized water and filtered through a 0.2 µm filter. The starting buffer for chromatofocusing were washed with DMEM three times by centrifugation (300 g, 5 min), resuspended in Iscove's serum-free medium (10 ml/testis) was bis(2-hydroxyethyl)imino-Tris(hydroxymethyl)methane (bis-Tris, 7.14 mmol/l, pH 7.0-7.2; Sigma). The elution buffer was Polybuffer supplemented with bovine serum albumin (BSA; 0.1%; ICN Biochemicals, High Wycombe, Bucks, UK), penicillin (100 IU/ml; Life 74 (Amersham Pharmacia Biotech) used at a 1:35 dilution at pH 3.0-3.2. A saturated solution of iminodiacetic acid was used to titrate Technologies Ltd., Paisley, UK) and streptomycin (100 µg/ml, Life Technologies Ltd.) before being incubated in 96-well plates (200 buffers to the correct pH and all buffers were degassed for a minimum of 4 h prior to use. µl/well) for 48 h at 37°C in an atmosphere of 95% air/5% CO 2 . After this period the medium was replaced with fresh culture medium Ampoules of FSH preparations (Gonal-F batch B3228, Puregon batch 9F073) were reconstituted in degassed bis-Tris (10 ml, 7.14 (100 µl final volume) containing the androgen substrate 19α-hydroxyandrostenedione (7.5 µmol/l), the phosphodiesterase inhibitor isobummol/l) containing 0.1% BSA at pH 7.0-7.2. A final dilution was made in bis-Tris such that 2.0 IU FSH in 8.5 ml was loaded onto the tylmethylxanthine (0.125 mmol/l; Sigma Chemical Co., Poole, Dorset, UK) and FSH (0-1000 IU/l) and the plates were incubated for a chromatofocusing Mono P column (4 ml) which was used in conjunction with a fast performance liquid chromatographic system (Amerfurther 24 h. The majority of contaminating germ cells were removed on exchange of culture medium. After 72 h in culture, samples (50 sham Pharmacia Biotech). The column was washed with NaCl (0.5 ml, 2 mol/l) to exchange the storage counter ion, prior to an µl) were assayed for oestradiol by specific radioimmunoassay. The effect of increasing concentrations of Puregon on oestradiol secretion equilibration with 30-50 ml bis-Tris (0.5 ml/min flow rate) until the column pH was equal to that of the start buffer. The sample (8.5 ml) by rat Sertoli cells is shown in Figure 1 . Similar dose-response relationships were obtained for Gonal-F (batch B3228) and Puregon was loaded onto the column and elution buffer was pumped at a flow rate of 0.5 ml/min to generate the pH gradient. Fractions (0.95 ml) (batch 9F073) in three separate experiments. Dilutions of Gonal-F when measured against the linear portion of the Puregon standard were collected into tubes containing 50 µl 2% BSA in distilled deionized water, such that the final concentration of BSA was 0.1%, curve gave parallel responses. Furthermore, a comparison of the slopes of the linear portion of the curves for Gonal-F and Puregon and their pH was adjusted to pH 7.4 with dilute NaOH. The run was continuous until the pH of the eluent was the same as that of the showed no significant difference (Student's t-test).
limit buffer. After completion of the pH gradient, NaCl (0.5 ml, 2 Serono Labs (UK) Ltd] and 7.5 µg for Puregon (from stated specific activity of 10 000 IU/mg in product data sheet), allowing the amount mol/l) was injected on to the column and eluted with Polybuffer (10 ml). All fractions, including the material below pI Ͻ3.25 (salt of protein in 10 kIU/l stock solutions of each of the preparations to be calculated. Furthermore, expression of this in molar terms is peak), were frozen and stored at -40°C until estimation of FSH immunoreactivity by Delfia ® (Wallac, Milton Keynes, UK). The mean possible from knowledge of the published data on respective mean molecular weight by sodium dodecyl sulphate (SDS)-polyacrylamide percentage recovery of FSH after chromatofocusing was 78.1 (95% confidence interval, 74.7-81.5; n ϭ 6).
gel electrophoresis, namely 42 000 for Gonal-F (Siebold, 1996) and 42 500 for Puregon (Olijve et al., 1996) . Published matrix-assisted Concanavalin A affinity chromatography laser desorption ionization (MALDI) mass spectrometry data for both Concanavalin A (con A) interacts with N-linked oligosaccharide these preparations are not available currently. The FSH immunoreacstructures according to their branching properties, such that tritivity in these stock solutions as measured by Delfia thus determined antennary, tetra-antennary and bisecting oligosaccharides (complex the immunopotency per (pico)mole. These specific activities and forms) do not bind to con A, bi-antennary and truncated hybrids molecular weights were similarly used in the expression (as ED 50 ) (intermediate complexity forms) bind weakly, and high mannose and of in-vitro bioactivity in molar terms. hybrid oligosaccharide (simple forms) bind firmly to con A All data are expressed as mean Ϯ SEM and there were three or (Cummings and Kornfeld, 1982) . more replicates in each experiment. FSH immunoreactivity in the Phosphate buffer (0.05 mol/l, pH 7.4) containing 0.1% BSA was pooled 0.25 pH unit samples following chromatofocusing was comused to prepare all eluents. Eluent (i) was phosphate buffer only, pared using Student's unpaired t-test. eluent (ii) was phosphate buffer containing 10 mmol/l α-D-methylglucopyranoside (α-MG; Sigma) and eluent (iii) was phosphate buffer containing 300 mmol/l α-D-methylmannopyranoside (α-MM, Sigma).
Results
Column regeneration solution (a) was 0.1 mol/l borate (pH 8.5), 
Immunopotency and biopotency of Gonal-F and Puregon

Charge distribution of Gonal-F and Puregon
Before use, the lectin columns (2.5 ml con A agarose, Sigma) were
The immunoreactive FSH distribution found for Gonal-F and equilibrated with five column volumes of prewash solution followed Puregon is shown in Figure 2 . The distributions were largely by 0.05 mol/l phosphate buffer. 1 IU/100 µl of each of the recombinant similar, with the bulk of the material focusing between pI 4.0 gonadotrophin preparations was loaded onto the column and allowed and 5.0, the percentages of the total FSH recovered for Gonalto interact for 10 min at room temperature. Unbound FSH was F and Puregon over this range being 66.0 Ϯ 1.8 and 72.0 Ϯ collected by passing 5 ml of eluent (i) down the column in 0.5 ml fractions. Weakly and firmly bound FSH was collected in a similar 1.8 respectively. In each case the median pI fell within the way by passing 25 ml of eluent (ii) and 13 ml of eluent (iii) 4.26-4.50 pH fraction. There were small differences in the respectively down the column. A total of 86 fractions was collected extremes of the distributions with more Gonal-F focusing and stored frozen at -40°C for subsequent FSH immunoassay. between pI 3.5 and 4.0 than Puregon (18.2 Ϯ 1.7 versus 9.8
Recoveries ranged from 73-113% (91.7 Ϯ 2.6, mean Ϯ SEM, Ϯ 1.8%; P ϭ 0.03) and less Gonal-F than Puregon focusing n ϭ 7). The column was regenerated using five column volumes of between pI 5.0 and 5.5 (6.7 Ϯ 1.2 versus 10.7 Ϯ 0.2%; regeneration solutions (a) and (b) in sequence followed by prewash P ϭ 0.03).
solution. The column was stored capped and upright in 0.05 mol/l phosphate buffer at 4°C.
Carbohydrate complexity of Gonal-F and Puregon
FSH immunofluorimetric assay
There were no differences between the two preparations, with Gonal-F and Puregon being respectively 9.3 Ϯ 1.3 versus 10.9 was adjusted to be identical to that of the fractions. Serial fractions Ϯ 1.6%, 76.6 Ϯ 2.4 versus 78.6 Ϯ 9.0%, and 14.1 Ϯ 4.2 were assayed at multiple dilutions in order to ensure that the versus 10.5 Ϯ 1.0%. glycoforms generated parallel standard curves to the FSH 78/549.
The relationship of the charge distribution and internal
The fractions did dilute in a parallel fashion. For example, analysis carbohydrate complexity of Gonal-F and Puregon to those of of variance revealed no differences between serial dilutions of the forms seen in the menstrual cycle is shown in Table I. unfractionated rFSH, material at pI 4.76-5.00 and in the salt peak (pI Ͻ3.25). Furthermore the Delfia assay has been demonstrated not to show differential recognition of purified FSH glycoforms (Oliver et al., 1999) . FSH was measured using the Delfia immunofluorimetric assay. Quality control samples were assayed in duplicate in each
Discussion
We have shown no significant differences between these two assay. Inter-assay coefficients of variation were 12.2% at 1.6 IU/l and recombinant gonadotrophin preparations in terms of their the rFSH, employing immunoextraction for Gonal-F in addition and throughout the menstrual cycle (Anobile et al., 1998) of complex forms. The reason for this may be that Chinese to ultrafiltration and chromatographic steps (see Howles, 1996) .
In addition there is negligible between-batch variability for hamster ovary cells do not have the enzymatic functions to construct the complex carbohydrate structures found in the Gonal-F (B3228 used here) and the previous clinical batch (B3209) (Horsman et al., 1999) . Similarly for Puregon 9F073 human. This difference appears, however, to be of no clinical importance since both Gonal-F and Puregon are highly bioac- (Talbot et al., 1999) varies little in terms of immunopotency, and, when compared using similar methodologies with our tive and clinically effective in vivo. Moreover, most of the evidence on the possibility of the different forms of FSH having previous published data on the pre-clinical batch (Org 32489), with respect to in-vitro biopotency, charge distribution different bioactivity relates to the various charged species. The techniques used do have their limitations, especially (Lambert et al., 1995) and carbohydrate complexity (Harris et al., 1996) . These findings lend weight to the argument that the rat Sertoli cell bioassay system. Not only does this utilize a single FSH response (oestradiol production) but there is also the rFSH preparations are highly consistent between batches.
Our data from the rFSH preparations reveal that they are a well-recognized inherent imprecision. Our calculations on ED 50 will also be affected by the relative imprecision of the most similar to the forms found in blood around mid-cycle with regard to charge but differ entirely with regard to published molecular weight data used to calculate biopotency. With these provisos, our studies have shown similar biopotency carbohydrate complexity, in that there is a predominance of intermediate complexity forms in the recombinant preparations in vitro and very little structural difference between the material
